Pre-market Hot Trades in US Stocks

Humacyte, up 7.25% in pre-market trading, has no significant news recently. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

Lam Research is up 3.62% in pre-market trading. Based on recent key news:

1. On June 26, the company deepened its focus on precision metal structural components manufacturing, with the semiconductor equipment structural components business steadily recovering, and the smart logistics equipment business expanding. The investment capacity is gradually being released, with expected net profits attributable to the parent company of 260 million, 349 million, and 424 million yuan for 2026-2028, respectively, and a "Buy" rating was given for the first coverage. Source: Kaiyuan Securities

2. On June 29, MarketBeat reported that although Lam Research currently has a "Moderate Buy" rating among analysts, top analysts believe there are five stocks that are more worthy of investment. Source: MarketBeat

3. On June 27, MarketBeat reported that Lam Research was not included in the list of five stocks recommended by top analysts. Source: MarketBeat The semiconductor industry is performing well overall, with significant capital inflow.

Top Gainers in Pre-market Trading of US Stocks

Nature's Way Pharmaceuticals is up 204.05% in pre-market trading. Based on recent key news:

1. On June 26, Nature's Way Pharmaceuticals announced the acquisition of Best Praise International Limited. This acquisition includes five patents from Best Praise related to drug development, with a total price of $10.751 million, paid through 4,376,552 shares of common stock. Following this announcement, the stock price surged.

2. On June 26, the company issued a statement indicating that this acquisition will expand its drug patent portfolio, and the transaction is expected to be completed in the third quarter of 2026. This move further enhances market confidence in the company's future development, driving the stock price up.

3. On June 27, the market reacted positively to the company's acquisition news, with significantly increased pre-market trading volume, showing investors' optimistic attitude towards the company's future prospects. The industry is performing well overall, with significant capital inflow.

Decoy Therapeutics is up 136.68% in pre-market trading. Based on recent key news:

1. On June 26, Decoy Therapeutics announced a private financing of up to $21 million. Following this announcement, the market is filled with confidence in the company's future development, leading to a significant increase in stock price.

2. On June 26, Decoy Therapeutics launched its innovative product Designable Multi-Antivirals (D-MAVs™) in Houston, aimed at targeting common viral mechanisms across multiple virus families. The launch of the new product further raised market expectations for the company, driving the stock price up On June 29, Decoy Therapeutics signed a lock-up agreement with Curvature Securities to support an orderly trading post-financing. This move has boosted investor confidence in the company's stock, leading to a continued rise in share prices. The biotechnology sector has shown strong performance recently, with significant capital inflows.

Inlif rose 60.81% in pre-market trading. Based on recent key news:

On June 26, TipRanks' AI analyst Spark rated Inlif stock as neutral, with a target price of $0.05. The analyst pointed out that the financial performance in 2025 is expected to deteriorate sharply, including loss results and negative cash flow, while the technical indicators are very weak, with momentum severely oversold and the stock price far below major moving averages, leading to price volatility. Recent market fluctuations have intensified, and risks need to be monitored